Department of Chemistry and Chemical Engineering, Guangzhou University, Guangzhou, China.
Department of Health Technology and Informatics, Hong Kong Polytechnic University, Hong Kong, Hong Kong.
Elife. 2023 Aug 15;12:e85131. doi: 10.7554/eLife.85131.
Recent research has shown that the adhesion G protein-coupled receptor F1 ( also known as ) is an oncogene. The evidence is mainly based on high expression of in numerous cancer types, and knockdown can reduce the cell migration, invasion, and proliferation. is, however, mostly expressed in the liver of healthy individuals. The function of in liver has not been revealed. Interestingly, expression level of hepatic is dramatically decreased in obese subjects. Here, the research examined whether has a role in liver metabolism.
We used recombinant adeno-associated virus-mediated gene delivery system, and antisense oligonucleotide was used to manipulate the hepatic expression level in diet-induced obese mice to investigate the role of in hepatic steatosis. The clinical relevance was examined using transcriptome profiling and archived biopsy specimens of liver tissues from non-alcoholic fatty liver disease (NAFLD) patients with different degree of fatty liver.
The expression of in the liver was directly correlated to fat content in the livers of both obese mice and NAFLD patients. Stearoyl-coA desaturase 1 (), a crucial enzyme in hepatic de novo lipogenesis, was identified as a downstream target of by RNA-sequencing analysis. Treatment with the liver-specific inhibitor MK8245 and specific shRNAs against in primary hepatocytes improved the hepatic steatosis of -overexpressing mice and lipid profile of hepatocytes, respectively.
These results indicate regulates hepatic lipid metabolism through controlling the expression of . Downregulation of expression can potentially serve as a protective mechanism to stop the overaccumulation of fat in the liver in obese subjects. Overall, the above findings not only reveal a new mechanism regulating the progression of NAFLD, but also proposed a novel therapeutic approach to combat NAFLD by targeting .
This work was supported by the National Natural Science Foundation of China (81870586), Area of Excellence (AoE/M-707/18), and General Research Fund (15101520) to CMW, and the National Natural Science Foundation of China (82270941, 81974117) to SJ.
最近的研究表明,黏附 G 蛋白偶联受体 F1(也称为)是一种癌基因。这一证据主要基于在许多癌症类型中高表达,并且敲低可以减少细胞迁移、侵袭和增殖。然而,在健康个体的肝脏中主要表达。在肝脏中的功能尚未揭示。有趣的是,肥胖个体肝中的表达水平显著降低。在这里,研究人员检查了是否在肝脏代谢中起作用。
我们使用重组腺相关病毒介导的基因传递系统,并用反义寡核苷酸来操纵饮食诱导肥胖小鼠肝脏中的表达水平,以研究在肝脂肪变性中的作用。使用转录组谱分析和非酒精性脂肪性肝病(NAFLD)患者不同程度脂肪肝的存档活检标本来检查临床相关性。
肝脏中表达与肥胖小鼠和 NAFLD 患者肝脏中的脂肪含量直接相关。硬脂酰辅酶 A 去饱和酶 1(),肝从头合成脂质中的关键酶,通过 RNA 测序分析被鉴定为的下游靶标。用肝特异性抑制剂 MK8245 和针对在原代肝细胞中的表达的特异性 shRNA 处理分别改善了过度表达的小鼠的肝脂肪变性和肝细胞的脂质谱。
这些结果表明通过控制的表达来调节肝脂质代谢。下调表达可能是阻止肥胖个体肝脏中脂肪过度积累的一种保护机制。总的来说,这些发现不仅揭示了一种新的机制来调节非酒精性脂肪性肝病的进展,而且还提出了一种通过靶向来治疗非酒精性脂肪性肝病的新的治疗方法。
本工作得到了中国国家自然科学基金(81870586)、卓越计划(AoE/M-707/18)和一般研究基金(15101520)资助(CMW),和中国国家自然科学基金(82270941、81974117)资助(SJ)。